Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015

Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005–2010

Sarah E. SmithComments to Author , Julia Ershova, Natalia Vlasova, Elena Nikishova, Irina Tarasova, Platon Eliseev, Andrey Maryandyshev, Igor G. Shemyakin, Ekaterina V. Kurbatova, and J. Peter Cegielski
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.E. Smith, J. Ershova, E. Kurbatova, J.P. Cegielski); Arkhangelsk Regional Tuberculosis Dispensary, Arkhangelsk, Russia (N. Vlasova, E. Nikishova, I. Tarasova, P. Eliseev, A.O. Maryandyshev); Northern State Medical University, Arkhangelsk (A.O. Maryandyshev); State Research Center for Applied Microbiology and Biotechnology, Obolensk, Russia (I.G. Shemyakin)

Main Article

Table 5

Risk factors for acquiring resistance to second-line companion drugs during MDR TB treatment, 153 patients, Arkhangelsk Oblast, Russia, 2005–2010*

Variable† Total Acquired resistance to ETA or PAS, no. (%)
p value‡
Yes No
Enrollment cohort
2005–2006 58 0 (0) 58 (100) 0.08
2007–2008 95 6 (6.3) 89 (93.7)
Thoracic surgery during current episode
Yes 2 1 (50) 1 (50) 0.08
No 151 5 (3.3) 146 (96.7)
Ever received OFX during current episode
Yes 133 2 (1.5) 131 (98.5) 0.003
No 20 4 (20) 16 (80)
Ever received MOX during current episode
Yes 28 5 (17.9) 23 (82.1) <0.001
No 125 1 (0.8) 124 (99.2)
Ever received a third-line drug during current episode
Yes 77 6 (7.8) 71 (92.2) 0.03
No 76 0 (0) 76 (100)

*OFX, ofloxacin; MDR TB, multidrug-resistant tuberculosis; MOX, moxifloxacin.
†Certain variables were tested for association but omitted from table because results were not statistically significant at α = 0.1.
‡Fisher exact test.

Main Article

Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.